An Open Label, Single Arm, Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Trial Profile

An Open Label, Single Arm, Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Buparlisib (Primary) ; Cetuximab (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Status changed from recruiting to completed, based on the results presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 02 Jun 2015 Interim results of buparlisib monotherapy in 37 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top